paraoxon has been researched along with Diabetes Mellitus, Type 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Mansori, A; Al-Ramadi, BK; Bashir, G; Fernández-Cabezudo, MJ; George, JA; Lorke, DE; Mohamed, YA; Petroianu, G; Qureshi, MM | 1 |
| Głogowska-Szelag, J; Kajdaniuk, D; Karpe, J; Kos-Kudła, B; Marek, B; Nowak, K; Nowak, M; Siemińska, L; Swietochowska, E; Wielkoszyński, T | 1 |
2 other study(ies) available for paraoxon and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Involvement of Acetylcholine Receptors in Cholinergic Pathway-Mediated Protection Against Autoimmune Diabetes.
Topics: Acetylcholinesterase; Animals; Atropine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; GPI-Linked Proteins; Hyperglycemia; Insulin-Secreting Cells; Male; Mecamylamine; Mice; Mice, Inbred C57BL; Muscarinic Antagonists; Nicotinic Antagonists; Paraoxon; Receptors, Muscarinic; Receptors, Nicotinic; Streptozocin | 2019 |
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.
Topics: Adult; Age Factors; Aged; Antioxidants; Aryldialkylphosphatase; C-Reactive Protein; Ceruloplasmin; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Paraoxon; Phenylenediamines; Sex Factors | 2010 |